Page last updated: 2024-11-07

spironolactone and Aging

spironolactone has been researched along with Aging in 34 studies

Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.

Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.

Research Excerpts

ExcerptRelevanceReference
"To investigate the effects of spironolactone on fibrosis and cardiac function in people at increased risk of developing heart failure."9.41The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial. ( Ahmed, FZ; Brunner La Rocca, HP; Clark, AL; Cleland, JGF; Collier, TJ; Cosmi, F; Cuthbert, J; Diez, J; Edelmann, F; Ferreira, JP; Girerd, N; González, A; Grojean, S; Hazebroek, M; Heymans, S; Khan, J; Latini, R; Mamas, MA; Mariottoni, B; McDonald, K; Mujaj, B; Pellicori, P; Petutschnigg, J; Pieske, B; Pizard, A; Rossignol, P; Rouet, P; Staessen, JA; Verdonschot, JAJ; Zannad, F, 2021)
" The Heart OMics in AGing (HOMAGE) trial aims to investigate the effects of spironolactone on serum markers of collagen metabolism and on cardiovascular structure and function in people at risk of developing HF and potential interactions with a marker of fibrogenic activity, galectin-3."9.34Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HO ( Ahmed, FZ; Brunner-La Rocca, HP; Clark, AL; Cleland, JGF; Collier, T; Cosmi, F; Cuthbert, JJ; Ferreira, JP; Girerd, N; González, A; Heymans, S; Latini, R; Mariottoni, B; Mujaj, B; Pellicori, P; Petutschnigg, J; Rossignol, P; Staessen, JA; Verdonschot, J; Zannad, F, 2020)
"To investigate the effects of spironolactone on fibrosis and cardiac function in people at increased risk of developing heart failure."5.41The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial. ( Ahmed, FZ; Brunner La Rocca, HP; Clark, AL; Cleland, JGF; Collier, TJ; Cosmi, F; Cuthbert, J; Diez, J; Edelmann, F; Ferreira, JP; Girerd, N; González, A; Grojean, S; Hazebroek, M; Heymans, S; Khan, J; Latini, R; Mamas, MA; Mariottoni, B; McDonald, K; Mujaj, B; Pellicori, P; Petutschnigg, J; Pieske, B; Pizard, A; Rossignol, P; Rouet, P; Staessen, JA; Verdonschot, JAJ; Zannad, F, 2021)
" The Heart OMics in AGing (HOMAGE) trial aims to investigate the effects of spironolactone on serum markers of collagen metabolism and on cardiovascular structure and function in people at risk of developing HF and potential interactions with a marker of fibrogenic activity, galectin-3."5.34Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HO ( Ahmed, FZ; Brunner-La Rocca, HP; Clark, AL; Cleland, JGF; Collier, T; Cosmi, F; Cuthbert, JJ; Ferreira, JP; Girerd, N; González, A; Heymans, S; Latini, R; Mariottoni, B; Mujaj, B; Pellicori, P; Petutschnigg, J; Rossignol, P; Staessen, JA; Verdonschot, J; Zannad, F, 2020)
"We report four cases of hyperkalemia induced by the association of spironolactone with ACE inhibitor in geriatric patients."3.70Elderly heart failure patients with drug-induced serious hyperkalemia. ( Swine, CH; Vanpee, D, 2000)
"Myocardial fibrosis increases arrhythmia vulnerability of the diseased heart."1.36Reduction of fibrosis-related arrhythmias by chronic renin-angiotensin-aldosterone system inhibitors in an aged mouse model. ( Boulaksil, M; de Bakker, JM; Engelen, MA; Hauer, RN; Herold, E; Houtman, MJ; Jansen, JA; Joles, JA; Noorman, M; Stein, M; van Rijen, HV; van Veen, TA, 2010)
"Spironolactone did not enhance water and electrolyte excretion."1.30Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. ( Chander, PN; Khanna, K; Rocha, R; Stier, CT; Zuckerman, A, 1998)
" On comparison of the pharmacokinetic parameters with the respective values of a control group of younger healthy female subjects, the serum concentrations in the elderly patients were found to be twice as high."1.27The influence of age and multimorbidity on the pharmacokinetics and metabolism of spironolactone. ( Abshagen, U; Horn, HJ; Mühlberg, W; Platt, D; Schmitt-Rüth, R; Vollmar, J, 1984)

Research

Studies (34)

TimeframeStudies, this research(%)All Research%
pre-199014 (41.18)18.7374
1990's6 (17.65)18.2507
2000's4 (11.76)29.6817
2010's7 (20.59)24.3611
2020's3 (8.82)2.80

Authors

AuthorsStudies
Pellicori, P2
Ferreira, JP2
Mariottoni, B2
Brunner-La Rocca, HP1
Ahmed, FZ2
Verdonschot, J1
Collier, T1
Cuthbert, JJ1
Petutschnigg, J2
Mujaj, B2
Girerd, N2
González, A2
Clark, AL2
Cosmi, F2
Staessen, JA2
Heymans, S2
Latini, R2
Rossignol, P2
Zannad, F2
Cleland, JGF2
Cuthbert, J1
Verdonschot, JAJ1
Brunner La Rocca, HP1
Mamas, MA1
Edelmann, F1
Pieske, B1
Khan, J1
McDonald, K1
Rouet, P1
Diez, J1
Hazebroek, M1
Grojean, S1
Pizard, A1
Collier, TJ1
Pitt, B1
Byrd, JB1
Hwang, MH2
Yoo, JK2
Luttrell, M2
Kim, HK2
Meade, TH2
English, M2
Nichols, WW1
Christou, DD2
Demiralay, C1
Agorastos, A1
Steiger, A1
Wiedemann, K1
Paar, M1
Pavenstädt, H1
Kusche-Vihrog, K1
Drüppel, V1
Oberleithner, H1
Kliche, K1
Talcott, S1
Jaffe, IZ1
Stein, M1
Boulaksil, M1
Jansen, JA1
Herold, E1
Noorman, M1
Joles, JA1
van Veen, TA1
Houtman, MJ1
Engelen, MA1
Hauer, RN1
de Bakker, JM1
van Rijen, HV1
Yau, JL1
Noble, J1
Seckl, JR1
Burton, LA1
McMurdo, ME1
Struthers, AD1
McMurray, JJ1
O'Meara, E1
Giordano, R1
Bo, M1
Pellegrino, M1
Vezzari, M1
Baldi, M1
Picu, A1
Balbo, M1
Bonelli, L1
Migliaretti, G1
Ghigo, E1
Arvat, E1
Hwang, HS1
Cirrincione, G1
Thomas, DP1
McCormick, RJ1
Boluyt, MO1
Platt, D2
Abshagen, U1
Mühlberg, W1
Horn, HJ1
Schmitt-Rüth, R1
Vollmar, J1
Johnson, MH1
Hyneck, ML1
Fujimura, A1
Sunaga, K1
Ebihara, A1
Rocha, R1
Chander, PN1
Khanna, K1
Zuckerman, A1
Stier, CT1
Kubisch, HM1
Mathialagan, S1
Gómez-Sánchez, EP1
Zemanová, Z1
Pácha, J2
Vanpee, D1
Swine, CH1
Svechnikova, NV1
Bekker, VI1
Magdich, LV1
Chowanetz, W1
Rückert, KH1
Juchems, R1
Gross-Fengels, F1
Garg, BD1
Kourounakis, P1
Tuchweber, B1
Kitani, K1
Kanai, S1
Miura, R1
Morita, Y1
Kasahara, M1
Sato, N1
Kamada, T1
Suematsu, T1
Abe, H1
Furuyama, F1
Hagihara, B1
Svitasheva, NG1
Kalish, EE1
Logvinenko, NS2
Solenov, EI2
Khlebodarova, TM1
Ivanova, LN1
Broude, NE1
Monastyrskaia, GS1
Caine, M1
Popp, M1
Capek, K1
Guibert, EE1
Rodriguez, JV1
Garcia, G1
Rodriguez Garay, EA1
Massie, B1
Klaassen, CD1
Dunihue, FW1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
"Bioprofiling Response to Mineralocorticoid Receptor Antagonists for the Prevention of Heart Failure. A Proof of Concept Clinical Trial Within the EU FP 7 (European Union FP7) HOMAGE Programme Heart OMics in AGing "[NCT02556450]Phase 2528 participants (Actual)Interventional2016-01-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for spironolactone and Aging

ArticleYear
Mineralocorticoid antagonism: a novel way to treat sarcopenia and physical impairment in older people?
    Clinical endocrinology, 2011, Volume: 75, Issue:6

    Topics: Aged; Aged, 80 and over; Aging; Humans; Mineralocorticoid Receptor Antagonists; Mobility Limitation;

2011

Trials

7 trials available for spironolactone and Aging

ArticleYear
Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HO
    European journal of heart failure, 2020, Volume: 22, Issue:9

    Topics: Aged; Aging; Biomarkers; Diabetes Mellitus, Type 2; Female; Fibrosis; Heart Failure; Humans; Male; N

2020
The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial.
    European heart journal, 2021, 02-11, Volume: 42, Issue:6

    Topics: Aged; Aging; Biomarkers; Female; Fibrosis; Heart Failure; Humans; Male; Peptide Fragments; Procollag

2021
Role of mineralocorticoid receptors in arterial stiffness in human aging.
    Experimental gerontology, 2013, Volume: 48, Issue:8

    Topics: Aged; Aging; Blood Pressure; Cross-Over Studies; Double-Blind Method; Eplerenone; Female; Humans; Ma

2013
Sleep EEG effects of anti-gluco- and anti-mineralocorticoids in old-aged men: pilot study.
    Psychiatry and clinical neurosciences, 2014, Volume: 68, Issue:5

    Topics: Aged; Aged, 80 and over; Aging; Electroencephalography; Humans; Male; Mifepristone; Mineralocorticoi

2014
Acute effect of mineralocorticoid receptor antagonism on vascular function in healthy older adults.
    Experimental gerontology, 2016, Volume: 73

    Topics: Aged; Aging; Biomarkers; Blood Proteins; Brachial Artery; Cross-Over Studies; Double-Blind Method; E

2016
Hypothalamus-pituitary-adrenal hyperactivity in human aging is partially refractory to stimulation by mineralocorticoid receptor blockade.
    The Journal of clinical endocrinology and metabolism, 2005, Volume: 90, Issue:10

    Topics: Adrenocorticotropic Hormone; Adult; Aged; Aging; Canrenoic Acid; Circadian Rhythm; Dehydroepiandrost

2005
[Effect of aldactone on the mineralocorticoid function of the adrenal cortex and the sodium and potassium content in the blood of middle-aged and elderly persons].
    Vrachebnoe delo, 1978, Issue:8

    Topics: Adrenal Cortex; Adult; Aged; Aging; Aldosterone; Clinical Trials as Topic; Drug Evaluation; Erythroc

1978

Other Studies

26 other studies available for spironolactone and Aging

ArticleYear
Detection of patients at risk of developing heart failure responsive to mineralocorticoid receptor antagonists (MRAs): new insights and opportunities.
    European heart journal, 2021, 02-11, Volume: 42, Issue:6

    Topics: Aging; Fibrosis; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; ras Proteins; Spiron

2021
Endothelial sodium channels trigger endothelial salt sensitivity with aging.
    Hypertension (Dallas, Tex. : 1979), 2014, Volume: 64, Issue:2

    Topics: Aging; Amiloride; Animals; Aorta; Endothelium, Vascular; Epithelial Sodium Channels; Mice; Sodium Ch

2014
Reduction of fibrosis-related arrhythmias by chronic renin-angiotensin-aldosterone system inhibitors in an aged mouse model.
    American journal of physiology. Heart and circulatory physiology, 2010, Volume: 299, Issue:2

    Topics: Age Factors; Aging; Angiotensin II Type 1 Receptor Blockers; Animals; Arrhythmias, Cardiac; Blood Pr

2010
11beta-hydroxysteroid dehydrogenase type 1 deficiency prevents memory deficits with aging by switching from glucocorticoid receptor to mineralocorticoid receptor-mediated cognitive control.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2011, Mar-16, Volume: 31, Issue:11

    Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Aging; Analysis of Variance; Animals; Cognition; Cortic

2011
Treatment of heart failure with spironolactone--trial and tribulations.
    The New England journal of medicine, 2004, Aug-05, Volume: 351, Issue:6

    Topics: Adrenergic beta-Antagonists; Aging; Aldosterone; Drug Therapy, Combination; Glomerular Filtration Ra

2004
Aldosterone antagonism fails to attenuate age-associated left ventricular fibrosis.
    The journals of gerontology. Series A, Biological sciences and medical sciences, 2007, Volume: 62, Issue:4

    Topics: Aging; Aldosterone; Animals; Atrial Natriuretic Factor; Collagen; Collagen Type III; Female; Fibrosi

2007
The influence of age and multimorbidity on the pharmacokinetics and metabolism of spironolactone.
    Archives of gerontology and geriatrics, 1984, Volume: 3, Issue:2

    Topics: Aged; Aging; Blood Proteins; Canrenone; Chromatography, High Pressure Liquid; Disease; Erythrocyte C

1984
Comparison of methods for estimating digoxin dosing regimens: further analysis.
    American journal of hospital pharmacy, 1981, Volume: 38, Issue:10

    Topics: Adult; Aged; Aging; Creatinine; Digoxin; Female; Humans; Kidney; Male; Middle Aged; Spironolactone

1981
Administration time-dependent change in the effect of spironolactone in aged rats.
    Life sciences, 1994, Volume: 55, Issue:4

    Topics: Aging; Animals; Drug Administration Schedule; Male; Rats; Rats, Wistar; Sodium; Spironolactone

1994
Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats.
    Hypertension (Dallas, Tex. : 1979), 1998, Volume: 31, Issue:1 Pt 2

    Topics: Aging; Animals; Body Weight; Brain; Cerebrovascular Disorders; Delayed-Action Preparations; Diuresis

1998
Modulation of blood pressure in the Dahl SS/jr rat by embryo transfer.
    Hypertension (Dallas, Tex. : 1979), 1998, Volume: 31, Issue:1 Pt 2

    Topics: Adult; Aging; Animals; Blood Pressure; Cerebral Ventricles; Embryo Transfer; Female; Genotype; Human

1998
Localization of Na,K-ATPase activity in developing rat distal colon: role of corticosteroids.
    Mechanisms of ageing and development, 1998, Mar-16, Volume: 101, Issue:1-2

    Topics: 4-Nitrophenylphosphatase; Adrenal Cortex Hormones; Adrenalectomy; Aging; Aldosterone; Animals; Colon

1998
Elderly heart failure patients with drug-induced serious hyperkalemia.
    Aging (Milan, Italy), 2000, Volume: 12, Issue:4

    Topics: Aged; Aging; Angiotensin-Converting Enzyme Inhibitors; Diuretics; Dose-Response Relationship, Drug;

2000
[Therapy of the bronchitic syndrome in the elderly].
    Fortschritte der Medizin, 1977, Aug-18, Volume: 95, Issue:31

    Topics: Aged; Aging; Anti-Bacterial Agents; Breathing Exercises; Bronchitis; Chronic Disease; Cromolyn Sodiu

1977
Influence of age and spironolactone on lysosomal enzyme activities, DNA and protein content of the rat liver after partial hepatectomy.
    Gerontology, 1979, Volume: 25, Issue:2

    Topics: Acetylglucosaminidase; Aging; Animals; Cathepsins; DNA; Female; Glucuronidase; Hepatectomy; Liver; L

1979
Fine structural changes in the liver of young and old rats as influenced by microsomal enzyme inducers.
    Gerontology, 1979, Volume: 25, Issue:6

    Topics: Aging; Animals; Dexamethasone; Endoplasmic Reticulum; Enzyme Induction; Liver; Male; Microsomes, Liv

1979
The effect of ageing on the biliary excretion of ouabain in the rat.
    Experimental gerontology, 1978, Volume: 13, Issue:1-2

    Topics: Aging; Animals; Bile; Male; Ouabain; Rats; Spironolactone; Time Factors

1978
Cadmium toxicity and liver mitochondria. II. Protective effect of hepatic soluble fraction against cadmium-induced mitochondrial dysfunction.
    Journal of biochemistry, 1978, Volume: 84, Issue:1

    Topics: Adenosine Diphosphate; Aging; Animals; Cadmium; Cytochromes; Cytosol; Liver; Male; Mitochondria, Liv

1978
[The age-related characteristics of the hormonal regulation of Na+, K(+)-ATPase activity in the kidney cortex of rats].
    Biulleten' eksperimental'noi biologii i meditsiny, 1992, Volume: 114, Issue:8

    Topics: Adrenalectomy; Aging; Aldosterone; Animals; Kidney Cortex; Kidney Tubules, Collecting; Kidney Tubule

1992
[The hormonal regulation of mRNA Na,K-ATPase expression in rat kidneys in postnatal ontogeny].
    Tsitologiia, 1991, Volume: 33, Issue:11

    Topics: Adrenalectomy; Aging; Aldosterone; Animals; Dexamethasone; Enzyme Induction; Gene Expression Regulat

1991
Medical management of prostatic hyperplasia.
    Comprehensive therapy, 1986, Volume: 12, Issue:12

    Topics: Adrenergic alpha-Antagonists; Aged; Aging; Bromocriptine; Cyproterone; Humans; Male; Phenoxybenzamin

1986
Corticosteroid regulation of Na+ and K+ transport in the rat distal colon during postnatal development.
    Journal of developmental physiology, 1988, Volume: 10, Issue:6

    Topics: Adrenal Cortex Hormones; Adrenalectomy; Aging; Aldosterone; Amiloride; Animals; Animals, Suckling; C

1988
Biochemical and morphometric analysis of the effect of spironolactone on the livers from immature and adult rats.
    Archives internationales de pharmacodynamie et de therapie, 1987, Volume: 290, Issue:2

    Topics: Aging; Animals; Body Weight; Cell Nucleus; Cytoplasm; Liver; Macromolecular Substances; Male; Organ

1987
Updated diagnosis and management of congestive heart failure.
    Geriatrics, 1986, Volume: 41, Issue:3

    Topics: Aged; Aging; Angiography; Diagnosis, Differential; Diuretics; Echocardiography; Female; Heart Failur

1986
Stimulation of the development of the hepatic excretory mechanism for ouabain in newborn rats with microsomal enzyme inducers.
    The Journal of pharmacology and experimental therapeutics, 1974, Volume: 191, Issue:2

    Topics: Aging; Animals; Animals, Newborn; Bile; Enzyme Induction; Liver; Methylcholanthrene; Microsomes, Liv

1974
Reversal of the reduced juxtaglomerular cell granularity (GCI) in old rats.
    Journal of gerontology, 1971, Volume: 26, Issue:3

    Topics: Adrenal Insufficiency; Adrenalectomy; Aging; Animals; Cortisone; Female; Juxtaglomerular Apparatus;

1971